• Home
  •  / ReShape Lifesciences

ReShape Lifesciences

OverviewSuggest Edit

ReShape Lifesciences, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The Company develops the vBloc System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness.
TypePublic
Founded2002
HQSan Clemente, USMap
Websitereshapelifesciences.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)43(-48%)
Revenue (FY, 2019)$15.1 M(+2388%)
Share Price (May 2020)$3.7 (-8%)

Key People/Management at ReShape Lifesciences

Barton P. Bandy

Barton P. Bandy

President, Chief Executive Officer & Director
Dan Gladney

Dan Gladney

Board Member
Raj Nihalani

Raj Nihalani

Chief Technology Officer & Business Development
Kevin Condrin

Kevin Condrin

Senior Vice President, Commercial
Dov Gal

Dov Gal

Vice President, Regulatory and Clinical Affairs and Compliance Officer
Vipul Shah

Vipul Shah

Senior Vice President, Operations and R&D
Show more

ReShape Lifesciences Office Locations

ReShape Lifesciences has an office in San Clemente
San Clemente, US (HQ)
1001 Calle Amanecer
San Clemente, US
100 Calle Iglesia
Show all (2)

ReShape Lifesciences Financials and Metrics

ReShape Lifesciences Revenue

ReShape Lifesciences's revenue was reported to be $15.09 m in FY, 2019
USD

Revenue (Q1, 2020)

2.8m

Gross profit (Q1, 2020)

1.5m

Gross profit margin (Q1, 2020), %

53.9%

Net income (Q1, 2020)

(4.3m)

EBIT (Q1, 2020)

(4.1m)

Market capitalization (21-May-2020)

20.5m

Closing stock price (21-May-2020)

3.7

Cash (31-Mar-2020)

2.1m

EV

24.9m
ReShape Lifesciences's current market capitalization is $20.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

311.5k292.0k786.7k1.3m606.7k15.1m

Revenue growth, %

(6%)169%

Cost of goods sold

231.5k125.0k431.5k936.4k164.3k5.8m

Gross profit

80.0k167.0k355.2k350.8k442.4k9.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

123.1k188.4k79.0k64.0k72.0k276.0k296.8k40.0k93.1k360.0k950.0k653.4k350.2k3.1m4.5m3.5m2.8m

Cost of goods sold

85.5k146.0k30.8k23.3k40.1k155.3k146.6k29.5k54.5k214.5k829.0k634.8k263.9k843.0k1.6m1.4m1.3m

Gross profit

37.6k42.4k48.2k40.7k31.9k120.7k150.1k10.5k38.6k145.5k121.0k18.6k86.3k2.2m2.9m2.1m1.5m

Gross profit Margin, %

31%23%61%64%44%44%51%26%41%40%13%3%25%73%64%60%54%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

28.5m22.3m23.3m11.6m7.9m3.3m10.2m5.5m2.9m

Accounts Receivable

52.4k17.7k2.8k57.9k143.7k488.6k916.8k4.1m

Prepaid Expenses

804.8k571.7k546.7k421.7k831.5k467.8k1.3m1.7m

Inventories

1.1m1.3m1.1m980.5k1.7m1.8m2.8m984.7k1.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

27.2m32.4m20.5m26.6m27.2m29.4m23.1m21.1m24.4m21.7m16.3m11.4m4.8m12.3m11.2m11.5m6.8m18.7m11.2m23.4m841.6k1.9m472.9k1.8m4.4m7.7m2.1m

Accounts Receivable

123.1k16.9k52.6k18.6k17.0k53.3k1.5k112.5k25.1k55.0k182.5k191.7k68.2k109.4k333.1k962.4k446.0k532.1k3.9m4.6m3.0m3.1m

Prepaid Expenses

912.6k716.4k776.0k634.8k558.4k584.1k607.2k570.3k618.7k353.1k241.6k463.0k338.4k232.6k873.5k462.1k371.4k401.8k536.9k252.5k723.1k919.5k601.1k2.5m2.3m1.8m2.0m

Inventories

1.0m1.1m1.6m1.3m1.4m1.2m1.1m895.3k915.5k1.1m1.3m1.4m1.9m2.0m2.1m1.7m1.4m1.6m2.8m2.1m1.1m1.0m1.3m1.2m1.3m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(26.0m)(23.5m)(25.8m)(26.1m)(25.5m)(23.4m)(33.8m)(81.2m)(74.2m)

Depreciation and Amortization

304.0k227.0k174.6k188.9k188.6k139.6k925.5k440.6k1.7m

Inventories

(1.1m)(202.6k)143.3k147.4k(705.8k)(103.3k)68.4k2.0m(332.0k)

Accounts Payable

367.5k(224.6k)60.7k267.4k(222.6k)1.1m(223.4k)317.1k1.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(10.6m)(17.9m)(5.6m)(10.6m)(16.4m)(6.6m)(12.9m)(19.2m)(6.7m)(14.2m)(19.9m)(7.2m)(14.6m)(18.7m)(7.4m)(12.4m)(18.9m)(7.4m)(14.2m)(24.2m)(11.2m)(46.5m)(53.5m)(4.5m)(20.4m)(49.1m)(4.3m)

Depreciation and Amortization

143.3k223.6k68.0k125.6k177.6k42.1k81.6k124.4k47.5k95.0k141.9k48.7k97.4k146.3k39.4k78.7k109.4k29.1k68.8k158.6k764.5k1.5m2.3m433.0k863.0k1.3m4.0k

Inventories

65.9k(19.4k)(542.7k)(64.9k)(87.0k)98.9k36.8k232.7k212.4k(145.8k)(303.9k)(395.5k)(181.9k)(271.5k)(447.5k)86.7k272.3k(257.2k)21.8k716.1k1.8m(40.0k)(363.0k)(204.0k)60.0k

Accounts Payable

198.7k323.6k(187.6k)(431.7k)(271.2k)87.8k(127.9k)102.9k146.7k60.0k(75.8k)(347.2k)52.5k(198.9k)89.4k184.9k508.8k(778.1k)(388.6k)(788.2k)1.8m3.1m3.3m1.1m3.4m3.0m(865.0k)
show all
USDY, 2020

EV/EBIT

-6.1 x

EV/CFO

-7.7 x

Financial Leverage

1.7 x
Show all financial metrics

ReShape Lifesciences Online and Social Media Presence

ReShape Lifesciences's Trends

Embed Graph

ReShape Lifesciences News and Updates

September 26, 2018

Global Intragastric Balloons Market 2018-2022 - Key Vendors are Allurion Technologies, Apollo Endosurgery, Helioscopie, Obalon Therapeutics, ReShape Lifesciences & Spatz FGIA

DUBLIN, Sept. 26, 2018 /PRNewswire/ -- The "Global Intragastric Balloons Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Intragastric Balloons Market to grow at a CAGR of 25.18% during the period 2018-2022. The report has been prepared based on an...
May 14, 2018

ReShape Lifesciences' (RSLS) CEO Dan Gladney on Q1 2018 Results - Earnings Call Transcript

April 02, 2018

ReShape Lifesciences' (RSLS) CEO Dan Gladney on Q4 2017 Results - Earnings Call Transcript

ReShape Lifesciences Blogs

Show more

 ReShape Lifesciences Frequently Asked Questions

  • When was ReShape Lifesciences founded?

    ReShape Lifesciences was founded in 2002.

  • Who are ReShape Lifesciences key executives?

    ReShape Lifesciences's key executives are Barton P. Bandy, Dan Gladney and Raj Nihalani.

  • How many employees does ReShape Lifesciences have?

    ReShape Lifesciences has 43 employees.

  • What is ReShape Lifesciences revenue?

    Latest ReShape Lifesciences annual revenue is $15.1 m.

  • What is ReShape Lifesciences revenue per employee?

    Latest ReShape Lifesciences revenue per employee is $350.9 k.

  • Who are ReShape Lifesciences competitors?

    Competitors of ReShape Lifesciences include Decibel Therapeutics, HDL Therapeutics and BioCardia.

  • Where is ReShape Lifesciences headquarters?

    ReShape Lifesciences headquarters is located at 1001 Calle Amanecer, San Clemente.

  • Where are ReShape Lifesciences offices?

    ReShape Lifesciences has an office in San Clemente.

  • How many offices does ReShape Lifesciences have?

    ReShape Lifesciences has 2 offices.